Karla Barker 
Anthropic CEO Dario Amodei returned to X with a familiar forecast. In a two-part reply to Gavin Baker, the CIO of Atreides Management, Amodei said he still believes AI can make it possible to cure most human diseases within five to ten years. The post had drawn more than 14 million views as of this writing. Even Elon Musk reacted to the thread.
Why this reply happened now
Baker had earlier talked about Anthropic on an investor podcast, mentioning that Amodei privately raised the idea that his company could end up as the only private company left, with governments running everything else. Baker then posted a broader criticism on X, arguing that Amodei had lost the regulation debate and should become a more positive voice for the AI industry.
Amodei pushed back on that framing. He pointed to his two major essays, one on risk and one on benefit, saying his messaging has been balanced. The benefit essay, Machines of Loving Grace, came out in October 2024. It argues that AI can compress 50 to 100 years of biological progress into 5 to 10.
A rare admission
The more interesting part was not the prediction. Amodei admitted that AI companies, including his own, have not delivered on their promises. He placed the blame squarely on the industry, not its critics. He also dismissed the idea of fixing public opinion through marketing. Promising to cure cancer, he said, now sounds like a cliché and feels deceptive. Actually curing it is the only thing that works.
Then came the near-term claim. Amodei said Anthropic is speeding up its work in biology and medicine, and expects major results in coming years with some early glimmers in the coming months.
Anthropic has been making moves
This is not just talk. Anthropic launched Claude for Life Sciences in October. It announced research partnerships with the Allen Institute and Howard Hughes Medical Institute in February. It also reportedly acquired stealth biotech startup Coefficient Bio in a stock deal worth around $400 million. Coefficient was founded by people from Genentech’s computational drug discovery group, and its team is joining Anthropic’s health and life sciences division.
A timeline that can be checked
Ten-year predictions are easy to ignore. The “early glimmers in months” promise is not. Amodei said that when Anthropic achieves something real, the world will hear about it loudly. Until then, he doesn’t want to make empty promises.
The timing is worth noting. Anthropic filed confidentially with the SEC in June. Its backers are reportedly modeling a $2 trillion valuation for a possible October listing. Those glimmers could land right around the same window. Whether that is coincidence or a deliberate setup may not matter. The claim is now on the record, and the clock is running.